BALTIMORE--(BUSINESS WIRE)--Introgen Therapeutics Inc.’s (NASDAQ:INGN) reported today the application of regulatory biomarker initiatives to advance the global licensure of ADVEXIN by identifying patient populations most likely to benefit from this cancer treatment. These data were invited for presentation at an international cell and gene therapy conference and were reported by Dr. Robert E. Sobol, Introgen’s senior vice president of Medical and Scientific Affairs, in a presentation titled “Critical Path and Oncology Biomarker Qualification Initiatives for the Late-Phase Development of ADVEXIN p53 Tumor Suppressor Therapy.”
